Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
MENS Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS
Other Working Capital · Q4 FY2024 · quarter ended Dec 2024
Other working capital declines year over year
Q4 FY2024 other working capital of $163 fell 65.5% year over year. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +91.2% a year.
Context
- Other working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 20.74M USD
- Year-over-year change
- +1495.4%
- 4-year CAGR
- +103.0%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.74M | +1495.4% |
| FY2024 | 2024-12-31 | (1.49M) | -232.7% |
| FY2023 | 2023-12-31 | 1.12M | -62.2% |
| FY2022 | 2022-12-31 | 2.97M | +142.6% |
| FY2021 | 2021-12-31 | 1.22M | — |
Other Working Capital vs competitors
How MENS compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Over three fiscal years its annual growth of +91.2% compares with a peer median of +1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $141.78M USD | -18.5% | — | 10.4% | |
| LTM Sep 2026 | $42.44M USD | +24575.6% | +82.5% | 6.5% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥37.72M CNY | +97.2% | -23.9% | 6.8% |
| LTM Jun 2026 | $33.43M USD | +6161.0% | +41.2% | — | |
| LTM Mar 2026 | $27.45M USD | -486.1% | — | — | |
| LTM Sep 2026 | $9.48M USD | +2409.0% | -50.7% | — | |
| LTM Jun 2026 | $5.51M USD | -157.6% | — | — | |
| LTM Sep 2026 | $1.83M USD | -124.3% | +1.7% | 29.7% | |
| LTM Mar 2026 | $1.52M USD | -103.4% | — | 0.2% | |
| LTM Jun 2026 | $1.24M USD | -89.9% | — | — | |
| LTM Dec 2024 | $1.49K USD | — | +91.2% | — | |
| Peer median (excluding MENS) | — | -54.2% | +1.7% | 6.8% | |
Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.24M | 2.94M | 1.12M | (1.49M) | 20.74M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21K | (28K) | (2K) | 1K | (1K) |
| Other Working Capital | 1.22M | 2.97M | 1.12M | (1.49M) | 20.74M |
| Other Non-Cash Items | 849K | 599K | 554K | 761K | (19.21M) |
| Operating Cash Flow | (1.98M) | (2.97M) | (2.6M) | (3.62M) | (3.04M) |
| Capital Expenditures | (137K) | (246K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.83M) | (292K) | 0 | 0 | (16.87M) |
| Sales of Investments | 664K | 1.93M | 95K | 0 | 16.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (13.51M) |
| Investing Cash Flow | (1.31M) | 1.39M | 95K | 0 | (13.51M) |
| Debt Repayment | (1.35M) | 3.61M | 2.47M | 2.2M | (24K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 17.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35K) | (276K) | (445K) | (213K) | (114K) |
| Financing Cash Flow | (1.38M) | 3.33M | 2.03M | 1.99M | 17.63M |
| Effect of Forex Changes | 67K | (31K) | (54K) | (7K) | (8K) |
| Net Change in Cash | (4.61M) | 1.72M | (532K) | (1.64M) | 1.08M |
| Free Cash Flow | (2.12M) | (3.22M) | (2.6M) | (3.62M) | (3.04M) |
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.